Search
Tislelizumab
go.drugbank.com/drugs/DB14922ApprovedInvestigationalTislelizumab is a humanized monoclonal IgG4 antibody against programmed death receptor-1 (PD-1). … It was engineered to have a nullified Fc portion, thus minimizing binding to FcγR on macrophages and limiting treatment resistance via antibody-dependent phagocytosis.
Categories: Programmed Death Receptor-1 Blocking AntibodyPiracetam
go.drugbank.com/drugs/DB09210ApprovedWithdrawnPiracetam has effects on the vascular system by reducing erythrocyte adhesion to the vascular endothelium, hindering vasospasms and facilitating microcirculation [A31532]. … It shares the same 2-oxo-pyrrolidone base structure with pyroglutamic acid and is a cyclic derivative of the neurotransmitter γ-aminobutyric acid (GABA).
Phenylpropanolamine
go.drugbank.com/drugs/DB00397ApprovedVet approvedWithdrawnCurrently, it is withdrawn from the market in Canada and the United States due to the risk for hemorrahgic strokes. … Phenylpropanolamine is a sympathomimetic agent that acts as a nonselective adrenergic receptor agonist and norepinephrine reuptake inhibitor.
Categories: Adrenergic beta-2 Receptor AgonistsTrifluoperazine
go.drugbank.com/drugs/DB00831ApprovedA phenothiazine with actions similar to chlorpromazine. It is used as an antipsychotic and an antiemetic.
Categories: Adrenergic alpha-1 Receptor Antagonists, Dopamine D2 Receptor AntagonistsCarglumic acid
go.drugbank.com/drugs/DB06775ApprovedInvestigationalCarglumic acid was approved by the U.S. Food and Drug Administration (FDA) on 18 March 2010. … Carglumic acid is a drug used for the treatment of hyperammonemia in patients with a deficiency in N-acetyl glutamate synthase.
Almitrine
go.drugbank.com/drugs/DB01430ApprovedIt is also reported to have a potentially beneficial effect in treating the noctural oxygen desaturation without impairing the quality of sleep. … It is used in the treatment of chronic obstructive pulmonary disease.
Osilodrostat
go.drugbank.com/drugs/DB11837ApprovedInvestigationalOsilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. … Cushing's disease is often the result of ACTH hypersecretion secondary to a pituitary tumor, and surgical resection of the tumour is generally the treatment of choice.
Lorpiprazole
go.drugbank.com/drugs/DB09195ApprovedLorpiprazole is a serotonin antagonist and reuptake inhibitor used for the treatment of major depressive disorder.[A31634] It is a piperazinyl-triazole derivative.[T83]
Categories: Serotonin Receptor Antagonists, Serotonin 5-HT2 Receptor AntagonistsZavegepant
go.drugbank.com/drugs/DB15688ApprovedInvestigationalSince they inhibit these mechanisms and desensitize neuronal circuits, the use of CGRP receptor antagonists is beneficial in the treatment of migraine. … Zavegepant is a third-generation CGRP receptor antagonist that is small in size and highly soluble. Due to its pharmacological properties, it can be administered intranasally.
Categories: Calcitonin Gene-Related Peptide Receptor AntagonistsTolfenamic acid
go.drugbank.com/drugs/DB09216ApprovedIt is used in the UK as a treatment for migraine under the name of Clotam.[L1292] In the US, it presents a Status class I by the FDA. … By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.[L1291]